PMP22 and Charcot-Marie-Tooth disease type 1A: In humans, PMP22 mRNA and PMP22 protein overexpression in nerve biopsies form patients with CMT1A indicates that increased PMP22 dosage is the most likely disease mechanism underlying CMT1A (16–19).